## **ForPatients**

by Roche

## Solid Tumors

## A Study to Evaluate Safety, Pharmacokinetics, and Preliminary Antitumor Activity of RO7444973 in Participants With Unresectable and/or Metastatic MAGE-A4-positive Solid Tumors

Trial Status Trial Runs In Trial Identifier
Terminated 6 Countries NCT05129280 2021-000624-35
BE43244

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

## Trial Summary:

This is a first-in-human, open-label, uncontrolled, multi-center, monotherapy dose-escalation and dose expansion study of RO7444973. The aim of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of RO7444973 in participants with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid tumors, carrying the HLA-A\*02:01 allele.

Hoffmann-La Roche Sponsor		Phase 1 Phase	
NCT05129280 2021-000624-35 BE43244 Trial Identifiers			
Eligibility Criteria:			
Gender All	Age >=18 Years		Healthy Volunteers